HOME >> MEDICINE >> NEWS
Tumor suppressor gene family may be key to new colon cancer drugs

In the hunt for new cancer drug targets, scientists from the Johns Hopkins Kimmel Cancer Center and the Howard Hughes Medical Institute have discovered mutations in a family of genes linked to more than a quarter of colon cancers, as well as several other common cancers including breast and lung. Their research, published in the May 21, 2004 issue of Science, reveals more options for creating personalized therapies tailored to counteract mutated gene pathways present in individual tumors.

"What makes this discovery significant is that we've found mutations that directly affect cancer development," says Victor Velculescu, M.D., Ph.D., senior author of the study and assistant professor at the Johns Hopkins Kimmel Cancer Center. "Most gene discoveries today focus on finding increased or decreased activity of a gene that may not affect cancer progression, akin to passengers on a bus that can't control the bus' speed or direction. What we've found are the brakes of the bus."

After analyzing 157 colon cancers, the research team found 77 mutations in six genes that make tyrosine phosphatases, enzymes that help coordinate signals that manage cellular growth, death, differentiation, and nearby tissue invasion. They normally work by turning off tumor growth, as so-called tumor suppressors, but in cancers these genes are mutated and no longer work properly. Because it is difficult to restore a mutated suppressor gene with cancer drugs, the investigators believe phosphatases themselves are not good drug targets. Yet, for every tyrosine phosphatase there is a matching enzyme, called a tyrosine kinase, which plays an opposite role, turning a pathway on and accelerating cellular events.

"If a bus' brakes are broken and they can't be fixed, another way to slow it down is to let up on the accelerator," explains Velculescu. "In this case, the faulty brakes are mutated tyrosine phosphatases and the accelerators are the tyrosine kinases." Tyrosine kinas
'"/>

Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
20-May-2004


Page: 1 2

Related medicine news :

1. Tumor-targeted immune cells cure prostate cancer in mice without causing systemic immune suppression
2. Tumor size alone not always best for gauging treatment response
3. Tumor suppressor genes predict bladder cancer future
4. Tumor characteristics may help predict survival in breast cancer patients
5. Tumor vaccine to begin clinical trials
6. Tumor size predicts survival in patients with lung cancer
7. Tumor vaccines via dendritic cells
8. Jefferson Scientists Show Tumor Characteristics May Help Explain Tumor Biology And Prognosis
9. Marker Found For The Most Malignant Brain Tumors
10. Stress And Surgery May Increase Development Of Cancerous Tumors
11. UCSF And Eight Other Medical Centers Chosen For National Cancer Institutes Pediatric Brain Tumor Consortium

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Tumor suppressor gene family may key new colon cancer drugs

(Date:11/22/2014)... 22, 2014 Setria® Glutathione is ... approved it for use “as a therapeutically active ... within the Therapeutic Goods (Listing) Notice 2014 (No. ... Hakko’s Setria® Glutathione will be exclusivity distributed in ... sources and imports fine chemicals to Australian manufacturers. ...
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that ... developed Type 2 diabetes due to its use continue ... underway in U.S. District Court, District of South Carolina, ... litigation will convene its next Status Conference on December ... Counsel for Plaintiffs and Defendants to meet and confer, ...
(Date:11/22/2014)... November 22, 2014 The Sports Conflict ... Roy Baroff to its team of conflict resolution professionals. ... player, coach, and referee. He has over 30 years experience ... beyond. , “I'm very excited to connect with SCI and ... related interests to a program with a complete sports focus,” ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Wright & ... AndroGel side-effects lawsuits have been scheduled between October ... Northern District of Illinois. U.S. District Judge Matthew F. ... a Case Management Order (CMO) on November 6, 2014 ... for attorneys to submit documents and other activities in ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
(Date:11/22/2014)... 2014 Many power shifts are occurring ... of patients in the biopharmaceutical market is impacting ... than ever, understanding how to effectively acquire, convert, ... essential. According to recent research ... spent about two-thirds of their patient-focused dollars on ...
(Date:11/21/2014)... Nov. 21, 2014 In September 2014, the ... carried out a new product development plan that started ... "limited edition" lab coat , aptly named "Vera ... surgery in the world. The new women,s designer lab ... with a sleek envelope collar, vertical princess and high ...
(Date:11/21/2014)... , Nov. 21, 2014  PTC Therapeutics, Inc. (NASDAQ: ... 2014 Legend of Technology Award for Vision, Innovation, and Leadership ... Chief Executive Officer. This award recognizes an individual who has ... New Jersey for several decades. ... Award," stated Stuart Peltz , Ph.D., CEO of PTC ...
Breaking Medicine Technology:New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
Cached News: